These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31751159)

  • 1. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review.
    Nieto Guevara J; Borys D; DeAntonio R; Guzman-Holst A; Hoet B
    Expert Rev Vaccines; 2020 Nov; 19(11):1011-1022. PubMed ID: 31751159
    [No Abstract]   [Full Text] [Related]  

  • 2. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
    Izurieta P; Nieto Guevara J
    Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
    Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
    Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.
    Izurieta P; Scherbakov M; Nieto Guevara J; Vetter V; Soumahoro L
    Hum Vaccin Immunother; 2022 Dec; 18(1):2013693. PubMed ID: 35020530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of experience with the pneumococcal non-typeable
    Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B
    Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.